Analysis of FHIT allelic imbalance/loss of heterozygosity and FHIT expression in cutaneous squamous cell carcinomas

Journal of Cutaneous Pathology

Volumn 35, Issue 9, 2008, Pages 816-825

  Gray, Sarah E ^a   Kay, Elaine ^a,b   Leader, Mary ^a,b   Mabruk, Mohamed ^a,c  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b BEAUMONT HOSPITAL   (Ireland)

^c UNIVERSITI BRUNEI DARUSSALAM   (Brunei Darussalam)

Author keywords

[No Author keywords available]

Indexed keywords

FRAGILE HISTIDINE TRIAD PROTEIN;

ALLELE; ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; EPIDERMIS; GENE EXPRESSION; GENE LOCUS; HETEROZYGOSITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRON; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA;

ACID ANHYDRIDE HYDROLASES; CARCINOMA, SQUAMOUS CELL; DNA, NEOPLASM; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOHISTOCHEMISTRY; LOSS OF HETEROZYGOSITY; MICRODISSECTION; MICROSATELLITE REPEATS; NEOPLASM PROTEINS; POLYMERASE CHAIN REACTION; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 49349092477     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/j.1600-0560.2007.00913.x     Document Type: Article

References (67)

1. Boni R, Schuster C, Nehrhoff B, Burg G. Epidemiology of skin cancer. Neuro Endocrinol Lett 2002 23 : 48.
2. World Health Organization. How common is skin cancer? URL http://www.who.int/uv/faq/skincancer/en/index1.html accessed on 19 February 2007 P. Non-melanoma skin cancer: what drives tumor development and progression? Carcinogenesis 2005 26 : 1657.
3. Armstrong BK, Kricker A. The epidemiology of UV induced skin cancer. J Photochem Photobiol B 2001 63 : 8.
4. Ohta M, Inoue H, Cotticelli MG, et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t (3; 8) breakpoint, is abnormal in digestive tract cancers. Cell 1996 84 : 587.
5. Wilke CM, Hall BK, Hoge A, Paradee W, Smith DI, Glover TW. FRA3B extends over a broad region and contains a spontaneous HPV16 integration site: direct evidence for the coincidence of viral integration sites and fragile sites. Hum Mol Genet 1996 5 : 187.
6. Huebner K, Garrison PN, Barnes LD, Croce CM. The role of the FHIT/FRA3B locus in cancer. Annu Rev Genet 1998 32 : 7.
7. Ingvarsson S, Sigbjornsdottir BI, Huiping C, Jonasson JG, Agnarsson BA. Alterations of the FHIT gene in breast cancer: association with tumor progression and patient survival. Cancer Detect Prev 2001 25 : 292.
8. Tomizawa Y, Nakajima T, Kohno T, Saito R, Yamaguchi N, Yokota J. Clinico-pathological significance of Fhit protein expression in stage I non-small cell lung carcinoma. Cancer Res 1998 58 : 5478.
9. Koda M, Yashima K, Kawaguchi K, et al. Expression of Fhit, Mlh1, and P53 protein in human gallbladder carcinoma. Cancer Lett 2003 199 : 131.
10. Kawaguchi K, Yashima K, Koda M, et al. Fhit expression in human gastric adenomas and intramucosal carcinomas: correlation with Mlh1 expression and gastric phenotype. Br J Cancer 2004 90 : 672.
11. Sasaki H, Haneda H, Yukiue H, Kobayashi Y, Yano M, Fujii Y. Decreased fragile histidine triad gene messenger RNA expression in lung cancer. Clin Lung Cancer 2006 7 : 412.
12. Nan KJ, Ruan ZP, Jing Z, et al. Expression of fragile histidine triad in primary hepatocellular carcinoma and its relation with cell proliferation and apoptosis. World J Gastroenterol 2005 11 : 228.
13. Zhao P, Song X, Nin YY, Lu YL, Li XH. Loss of fragile histidine triad protein in human hepatocellular carcinoma. World J Gastroenterol 2003 9 : 1216.
14. Yoshino K, Enomoto T, Nakamura T, et al. FHIT alterations in cancerous and non-cancerous cervical epithelium. Int J Cancer 2000 85 : 6.
15. Butler D, Collins C, Mabruk M, Leader MB, Kay EW. Loss of Fhit expression as a potential marker of malignant progression in preinvasive squamous cervical cancer. Gynecol Oncol 2002 86 : 144.
16. Tanimoto K, Hayashi S, Tsuchiya E, et al. Abnormalities of the FHIT gene in human oral carcinogenesis. Br J Cancer 2000 82 : 838.
17. Kujan O, Oliver R, Roz L, et al. Fragile histidine triad expression in oral squamous cell carcinoma and precursor lesions. Clin Cancer Res 2006 12 : 6723.
18. Mori M, Mimori K, Shiraishi T, et al. Altered expression of Fhit in carcinoma and precarcinomatous lesions of the esophagus. Cancer Res 2000 60 : 1177.
19. Lee EJ, Lee BB, Kim JW, et al. Aberrant methylation of fragile histidine triad gene is associated with poor prognosis in early stage esophageal squamous cell carcinoma. Eur J Cancer 2006 42 : 972.
20. Tai SK, Lee JI, Ang KK, et al. Loss of Fhit expression in head and neck squamous cell carcinoma and its potential clinical implication. Clin Cancer Res 2004 10 : 5554.
21. Siprashvili Z, Sozzi G, Barnes LD, et al. Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc Natl Acad Sci U S A 1997 94 : 13771.
22. Ji L, Fang B, Yen N, Fong K, Minna JD, Roth JA. Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. Cancer Res 1999 59 : 3333.
23. Sard L, Accornero P, Tornielli S, et al. The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control. Proc Natl Acad Sci U S A 1999 96 : 8489.
24. Roz L, Gramegna M, Ishii H, Croce CM, Sozzi G. Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in lung and cervical cancer cell lines. Proc Natl Acad Sci U S A 2002 99 : 3615.
25. Dumon K, Ishii H, Vecchione A, et al. Fragile histidine triad expression delays tumour development and induces apoptosis in human pancreatic cancer. Cancer Res 2001 61 : 4827.
26. Fong L, Fidanza V, Zanesi N, et al. Muir-Torre-like syndrome in Fhit-deficient mice. Proc Natl Acad Sci U S A 2000 97 : 4742.
27. Zanesi N, Fidanza V, Fong LY, et al. The tumor spectrum in FHIT-deficient mice. Proc Natl Acad Sci U S A 2001 98 : 10250.
28. Barnes LD, Garrison PN, Siprashvili Z, et al. Fhit, a putative tumor suppressor in humans, is a dinucleoside 5′, 5″′-P1, P3-triphosphate hydrolase. Biochemistry 1996 35 : 11529.
29. Murphy GA, Halliday D, McLennan AG. The Fhit tumor suppressor protein regulates the intracellular concentration of diadenosine triphosphate but not diadenosine tetraphosphate. Cancer Res 2000 60 : 2342.
30. Vartanian A, Prudovsky I, Suzuki H, Dal Pra I, Kisselev L. Opposite effects of cell differentiation and apoptosis on Ap3A/Ap4A ratio in human cell cultures. FEBS Lett 1997 415 : 160.
31. Chaudhuri AR, Khan IA, Prasad V, Robinson AK, Luduena RF, Barnes LD. The tumor suppressor protein Fhit. A novel interaction with tubulin. J Biol Chem 1999 274 : 24378.
32. Bianchi F, Magnifico A, Olgiati C, et al. FHIT-proteasome degradation caused by mitogenic stimulation of the EGF receptor family in cancer cells. Proc Natl Acad Sci U S A 2006 103 : 18981.
33. Golebiowski F, Szulc A, Szutowicz A, Pawelczyk T. Ubc9-induced inhibition of diadenosine triphosphate hydrolase activity of the putative tumor suppressor protein Fhit. Arch Biochem Biophys 2004 428 : 160.
34. Mimori K, Ishii H, Nagahara H, et al. FHIT is up-regulated by inflammatory stimuli and inhibits prostaglandin E2-mediated cancer progression. Cancer Res 2006 66 : 2683.
35. Nakagawa Y, Akao Y. Fhit protein inhibits cell growth by attenuating the signaling mediated by nuclear factor-kappaB in colon cancer cell lines. Exp Cell Res 2006 312 : 2433.
36. Ottey M, Han SY, Druck T, et al. Fhit-deficient normal and cancer cells are mitomycin C and UVC resistant. Br J Cancer 2004 91 : 1669.
37. Sikkink SK, Rehman I, Rees JL. Deletion mapping of chromosome 3p and 13q and preliminary analysis of the FHIT gene in human nonmelanoma skin cancer. J Invest Dermatol 1997 109 : 801.
38. Gray SE, Kay EW, Leader M, Mabruk MJ. Enhanced detection of microsatellite instability and mismatch repair gene expression in cutaneous squamous cell carcinomas. Mol Diagn Ther 2006 10 : 327.
39. Zauber NP, Sabbath-Solitare M, Marotta SP, McMahon L, Bishop DT. Comparison of allelic ratios from paired blood and paraffin-embedded normal tissue for use in a polymerase chain reaction to assess loss of heterozygosity. Mol Diagn 1999 4 : 29.
40. Butler D, Collins C, Mabruk M, Barry WC, Leader MB, Kay EW. Deletion of the FHIT gene in neoplastic and invasive cervical lesions is related to high-risk HPV infection but is independent of histopathological features. J Pathol 2000 192 : 502.
41. Nuovo GJ, Becker J. PCR in-situ hybridisation in viral detection. In Latchman DS, ed. PCR applications in pathology: principles and practice. Oxford : Oxford University Press, 1995 64.
42. Gray SE, Kay E, Leader M, Mabruk M. Analysis of p16 expression and allelic imbalance/loss of heterozygosity of 9p21 in cutaneous squamous cell carcinomas. J Cell Mol Med 2006 10 : 778.
43. Cawkwell L, Bell SM, Lewis FA, Dixon MF, Taylor GR, Quirke P. Rapid detection of allele loss in colorectal tumours using microsatellites and fluorescent DNA technology. Br J Cancer 1993 67 : 1262.
44. Greenspan DL, Connolly DC, Wu R, et al. Loss of FHIT expression in cervical carcinoma cell lines and primary tumors. Cancer Res 1997 57 : 4692.
45. Lee J, Soria J-C, Hassan K, et al. Loss of Fhit expression is a predictor of poor outcome in tongue cancer. Cancer Res 2001 61 : 837.
46. Kraggerud SM, Aman P, Holm R, et al. Alterations of the fragile histidine triad gene, FHIT, and its encoded products contribute to testicular germ cell tumorigenesis. Cancer Res 2002 62 : 512.
47. Yoshino K, Enomoto T, Nakamura T, et al. Aberrant FHIT transcripts in squamous cell carcinoma of the uterine cervix. Int J Cancer 1998 76 : 176.
48. Kannan K, Munirajan AK, Bhuvarahamurthy V, et al. FHIT gene mutations and single nucleotide polymorphism in Indian oral and cervical squamous cell carcinomas. Oral Oncol 2000 36 : 189.
49. Ko JY, Lee TC, Hsiao CF, et al. Definition of three minimal deleted regions by comprehensive allelotyping and mutational screening of FHIT, p16(INK4A), and p19(ARF) genes in nasopharyngeal carcinoma. Cancer 2002 94 : 1987.
50. Zochbauer-Muller S, Fong KM, Maitra A, et al. 5′ CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. Cancer Res 2001 61 : 3581.
51. Wali A, Srinivasan R, Shabnam MS, Majumdar S, Joshi K, Behera D. Loss of fragile histidine triad gene expression in advanced lung cancer is consequent to allelic loss at 3p14 locus and promoter methylation. Mol Cancer Res 2006 4 : 93.
52. Choi CH, Lee KM, Choi JJ, et al. Hypermethylation and loss of heterozygosity of tumor suppressor genes on chromosome 3p in cervical cancer. Cancer Lett 2007 255 : 26.
53. Riquelme E, Tang M, Baez S, et al. Frequent epigenetic inactivation of chromosome 3p candidate tumor suppressor genes in gallbladder carcinoma. Cancer Lett 2007 250 : 100.
54. Soma T, Kaganoi J, Kawabe A, Kondo K, Imamura M, Shimada Y. Nicotine induces the fragile histidine triad methylation in human esophageal squamous epithelial cells. Int J Cancer 2006 119 : 1023.
55. Goldberg M, Rummelt C, Laerm A, Helmbold P, Holbach LM, Ballhausen WG. Epigenetic silencing contributes to frequent loss of the fragile histidine triad tumour suppressor in basal cell carcinomas. Br J Dermatol 2006 155 : 1154.
56. Kalnina Z, Zayakin P, Silina K, Linē A. Alterations of pre-mRNA splicing in cancer. Genes Chromosomes Cancer 2005 42 : 342.
57. Smith DI, McAvoy S, Zhu Y, Perez DS. Large common fragile site genes and cancer. Semin Cancer Biol 2007 17 : 31.
58. Harwood CA, Proby CM. Human papillomaviruses and non-melanoma skin cancer. Curr Opin Infect Dis 2002 15 : 101.
59. Zimonjic DB, Druck T, Ohta M, et al. Positions of chromosome 3p14.2 fragile sites (FRA3B) within the FHIT gene. Cancer Res 1997 57 : 1166.
60. O'Connor DP, Kay EW, Leader M, Murphy GM, Atkins GJ, Mabruk MJ. Altered p53 expression in benign and malignant skin lesions from renal transplant recipients and immunocompetent patients with skin cancer: correlation with human papillomaviruses? Diagn Mol Pathol 2001 10 : 190.
61. Andachi H, Yashima K, Koda M, et al. Reduced Fhit expression is associated with mismatch repair deficiency in human advanced colorectal carcinoma. Br J Cancer 2002 87 : 441.
62. Sarli L, Bottarelli L, Azzoni C, et al. Abnormal Fhit protein expression and high frequency of microsatellite instability in sporadic colorectal cancer. Eur J Cancer 2004 40 : 1581.
63. Yao CC, Lin CY, Hu MB. Abnormal expression of fragile histidine triad (FHIT) and Mut S homolog 2 (MSH2) proteins in human sporadic colorectal carcinoma and their clinical significance. Ai Zheng 2004 23 : 310.
64. Guo Z, Johansson SL, Rhim JS, Vishwanatha JK. Fragile histidine triad gene expression in primary prostate cancer and in an in vitro model. Prostate 2000 43 : 101.
65. Yuge T, Nibu K, Kondo K, Shibahara J, Tayama N, Sugasawa M. Loss of FHIT expression in squamous cell carcinoma and premalignant lesions of the larynx. Ann Otol Rhinol Laryngol 2005 114 : 127.
66. Campiglio M, Pekarsky Y, Menard S, Tagliabue E, Pilotti S, Croce CM. FHIT loss of function in human primary breast cancer correlates with advanced stage of the disease. Cancer Res 1999 59 : 3866.
67. Huebner K, Croce CM. Cancer and the FRA3B/FHIT fragile locus: it's a HIT. Br J Cancer 2003 88 : 1501.